Hypoactive Sexual Desire Disorder
Conditions
Keywords
Natural Menopause, HSDD
Brief summary
This study is designed to evaluate efficacy and safety of a testosterone patch as treatment for low libido in naturally menopausal women who are taking estrogen or estrogen/progestin therapy.
Detailed description
Naturally menopausal women with hypoactive sexual desire disorder (HSDD) were randomized into a 52-week, multicenter, double-blind (DB), parallel-group, placebo-controlled study. Patients were stratified based on presence/absence of uterus and randomized to receive placebo or testosterone transdermal system. Patients had to maintain a stable dose of estrogen/progestin throughout the study. Patients who completed the first 52 weeks of the study were given the opportunity to participate in year 2-4 open-label (active treatment) study extension which was added to the protocol by amendment. Safety was assessed by adverse events, lipids, serum chemistry with hepatic, renal and carbohydrate metabois in evaluation, coagulation testing, and hermatology. Physical exam including clinical assessments of facial hair and acne were monitored.
Interventions
testosterone patch (300 mcg/day) patch changed 2 times/week, for one year
DRUGPlacebo patch
placebo patch changed twice a week for one year
Sponsors
Warner Chilcott
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
DOUBLE (Subject, Investigator)
Eligibility
Sex/Gender
FEMALE
Age
40 Years to 70 Years
Healthy volunteers
No
Inclusion criteria
Eligible women must: 1. Be 40-70 years old and in generally good health 2. Be post-menopausal with no spontaneous periods for 1 year 3. Be receiving a stable dose of hormone replacement therapy for at least 3 months prior to screening with the intention of maintaining that regimen. 4. Be, in her own judgment, in a stable, monogamous sexual relationship that is perceived to be secure and communicative, for at least one year prior to study entry 5. Meet the criteria for having hypoactive sexual desire disorder
Exclusion criteria
Eligible women must not: 1. Have received androgen therapy at any time during the past 3 months (during the past 7 months if therapy was an investigational implantable product) 2. Be experiencing any chronic or acute life stress relating to any major life change 3. Be experiencing depression and/or receiving medication for such illness or disorder 4. Have current severe skin problems (such as severe or cystic acne) or allergy to adhesives (like the ones in bandages) 5. Have had a major illness, active gall bladder disease, or gynecological or breast surgery within the last 6 months 6. Have a history of breast, endometrial, or other gynecological cancer at any time before study participation or other cancer within the last 5 years 7. Have diabetes, a history of cerebrovascular disease, thromboembolic disorders, heart attack, or angina at any time before study participation or thrombophlebitis within the last 5 years 8. Have abnormal laboratory test results upon initial screening for this study 9. Have previously participated in a clinical trial within 30 days or received an investigational medication within 30 days
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| To assess the efficacy of the transdermal system (TTS) as measured by the change from baseline in the frequency of total satisfying sexual activity captured by the Sexual Activity Log (SAL). | 12 months |
Secondary
| Measure | Time frame |
|---|---|
| To assess the efficacy measured by the change from baseline in sexual desire using personal distress as measured by the Personal Distress Scale (PDS) score; the other 6 domains of the Profile of Female Sexual function, and the other 8 SAL endpoints. | 12 months |
Countries
United States
Outcome results
None listed